Sami Gabbouj

Sami Gabbouj

Auto-generated profile, based on publicly available information

Sami Gabbouj

Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Neurobiology of Aging
Verified
Journal Article
Open access
SGSami Gabbouj
Sami Gabbouj
TNTeemu Natunen
Teemu Natunen
HKHennariikka Koivisto
Hennariikka Koivisto
KJKimmo Jokivarsi
Kimmo Jokivarsi
MTMari Takalo
Mari Takalo
Mikko HiltunenMikko Hiltunen
Mikko Hiltunen
Type 2 diabetes mellitus (T2DM) increases the risk for Alzheimer's disease (AD). Human AD brains show reduced glucose metabolism as measured by [18F]fluoro-2-deoxy-2-D-glucose positron emission tomography (FDG-PET). Here, we used 14-month-old wild-type (WT) and APPSwe/PS1dE9 (APP/PS1) transgenic mice to investigate how a single dose of intranasal insulin modulates brain glucose metabolism using FDG-PET and affects spatial learning and memory. We also assessed how insulin influences the activity of Akt1 and Akt2 kinases, the expression of glial and neuronal markers, and autophagy in the hippocampus. Intranasal insulin moderately increased glucose metabolism and specifically activated Akt2 and its downstream signaling in the hippocampus of WT, but not APP/PS1 mice. Furthermore, insulin differentially affected the expression of homeostatic microglia markers P2ry12 and Cx3cr1 and autophagy in the hippocampus of WT and APP/PS1 mice. We found no evidence that a single dose of intranasal insulin improves overnight memory. Our results suggest that intranasal insulin exerts diverse effects on Akt2 signaling, autophagy, and the homeostatic status of microglia depending on the degree of AD-related pathology.

1 January 2016 in Neurobiology of Disease
Verified
Journal Article
Closed access
TNTeemu Natunen
Teemu Natunen
MTMari Takalo
Mari Takalo
SKSusanna Kemppainen
Susanna Kemppainen
SLStina Leskelä
Stina Leskelä
MMMikael Marttinen
Mikael Marttinen
Mikko HiltunenMikko Hiltunen
Mikko Hiltunen

1 June 2016 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
KKKaisa M. A. Kurkinen
Kaisa M. A. Kurkinen
MMMikael Marttinen
Mikael Marttinen
LTLaura Turner
Laura Turner
TNTeemu Natunen
Teemu Natunen
PMPetra Mäkinen
Petra Mäkinen
Mikko HiltunenMikko Hiltunen
Mikko Hiltunen
Dysfunction and loss of synapses are early pathogenic events in Alzheimer's disease. A central step in the generation of toxic amyloid-β (Aβ) peptides is the cleavage of amyloid precursor protein (APP) by β-site APP-cleaving enzyme (BACE1). Here, we have elucidated whether downregulation of septin (SEPT) protein family members, which are implicated in synaptic plasticity and vesicular trafficking, affects APP processing and Aβ generation. SEPT8 was found to reduce soluble APPβ and Aβ levels in neuronal cells through a post-translational mechanism leading to decreased levels of BACE1 protein. In the human temporal cortex, we identified alterations in the expression of specific SEPT8 transcript variants in a manner that correlated with Alzheimer's-disease-related neurofibrillary pathology. These changes were associated with altered β-secretase activity. We also discovered that the overexpression of a specific Alzheimer's-disease-associated SEPT8 transcript variant increased the levels of BACE1 and Aβ peptides in neuronal cells. These changes were related to an increased half-life of BACE1 and the localization of BACE1 in recycling endosomes. These data suggest that SEPT8 modulates β-amyloidogenic processing of APP through a mechanism affecting the intracellular sorting and accumulation of BACE1.